Emergent BioSolutions Inc.

EBS

US29089Q1058

Pharmaceuticals

Market Closed - Nyse Other stock markets 04:00:03 2026-03-10 pm EDT			5-day change	1st Jan Change
8.390 ^USD	+0.48%		-6.67%	-32.12%

Mar. 03	Emergent BioSolutions Inc. Announces Appointment of John D. Fowler, Jr. as Board Director and member of Audit and Finance Committee, Effective March 1, 2026	CI
Mar. 03	Emergent BioSolutions announces appointment of John D. Fowler, Jr. to board of directors	RE

Top Midday Decliners

Published on 01/15/2026 at 02:34 pm EST

MT Newswires

This article is reserved for members

Unlock the article: REGISTER NOW!

100% Free Registration

Already a customer? Log In

Latest news about Emergent BioSolutions Inc.

Mar. 03	Emergent BioSolutions Inc. Announces Appointment of John D. Fowler, Jr. as Board Director and member of Audit and Finance Committee, Effective March 1, 2026	CI
Mar. 03	Emergent BioSolutions announces appointment of John D. Fowler, Jr. to board of directors	RE
Feb. 26	Emergent BioSolutions Inc., Q4 2025 Earnings Call, Feb 26, 2026
Feb. 26	Emergent BioSolutions Inc. announces an Equity Buyback for $50 million worth of its shares.	CI
Feb. 26	Tranche Update on Emergent BioSolutions Inc.'s Equity Buyback Plan announced on May 7, 2025.	CI
Feb. 26	Emergent BioSolutions Inc. Provides Earnings Guidance for the First Quarter and Full Year 2026	CI
Feb. 26	Emergent BioSolutions Inc. Reports Earnings Results for the Fourth Quarter and Full Year Ended December 31, 2025	CI
Feb. 26	Emergent BioSolutions Inc. Announces Approximately $140 Million in Contract Awards with the Government of Canada, Strengthening Canada's Leadership in Health Preparedness	CI
Feb. 13	Emergent BioSolutions Says FDA Approves Supplemental NDA for Nasal Spray Product	MT
Feb. 13	Emergent BioSolutions Receives U.S. FDA Approval of Supplemental New Drug Application for NARCAN® Nasal Spray Multipacks	CI
Feb. 12	Emergent BioSolutions Gets FDA Greenlight for Multipacks of Narcan	DJ
Jan. 31	Emergent BioSolutions Inc. authorizes a Buyback Plan.	CI
Jan. 16	Powell Investigation Upends Final Stretch of Fed Chair Contest	DJ
Jan. 15	Top Midday Decliners	MT
Jan. 15	Emergent announces resolution of New York attorney general investigation	RE

Chart Emergent BioSolutions Inc.

Duration

Period

EBS: Dynamic Chart

Emergent BioSolutions, Inc. is a life sciences company. It is focused on providing preparedness and response solutions addressing accidental, deliberate and naturally occurring public health threats. Its solutions include a product portfolio, a product development portfolio, and a Bioservices portfolio. Its segments include Commercial Products, MCM Products, and Services Segment. Commercial Products segment include NARCAN (naloxone HCl). MCM Products segment consists of its Anthrax - MCM, Smallpox - MCM and Other Products. Services segment consisting of its Bioservices offerings. NARCAN (naloxone HCl) Nasal Spray, an intranasal formulation of naloxone is developed for the emergency treatment of known or suspected opioid overdose as manifested by respiratory and/or central nervous system depression. Its portfolio of Bioservices consists of three but interrelated service pillars, such as development services (process and analytical development) and drug substance manufacturing.

Employees

900

Sector

Pharmaceuticals

More about the company